A bipartisan group of lawmakers has asked the U.S. government to consider new rules restricting U.S. biotech companies from conducting clinical trials with entities linked to the Chinese military.
In a Jan. 9 letter to Commerce Secretary Gina Raimondo, the House Select Committee on the Chinese Communist Party said the proposed restrictions will “help ensure U.S. biotechnology does not fall into the hands of the PRC,” referring to the acronym of communist China’s official name, the People’s Republic of China.
The letter, signed by Reps. John Moolenaar (R-Mich.) and Raja Krishnamoorthi (D-Ill.), chair and ranking member of the committee, respectively, along with Rep. Neal Dunn (R-Fla.), said biotech competition between the United States and the PRC “will not only have implications for our national and economic security, but also for the future of healthcare and the security of American medical data.”…